CMB International Securities | Equity Research | Company Update



招商银行全资附属机构 A Wholly Owned Subsidiary Of China Merchants Ban

Zhejiang Jingsheng (300316 CH)

Mega order intake to boost earnings in 2022E-23E; Raise earnings forecast and TP

Jingsheng announced last night that the Company won a contract of RMB6.08bn from Ningxia Zhonghuan (a subsidiary of **Zhonghuan [002129 CH, NR]**) to deliver automated crystal growing furnaces. We see this as a big positive to Jingsheng, given that the contract amount represents an addition of 53% on top of Jingsheng's backlog of RMB11.5bn (as at end-Jun 2021). The new contract reaffirms our confidence on the robust solar capex story. Given that Jingsheng will start the product delivery to Ningxia Zhonghuan in Nov 2021, we revise up our 2022E-23E earnings forecast by 17% for each year. We revise up our TP to RMB112. Reiterate **BUY** with conviction.

- Details of the contract. On 31 Aug, Jingsheng signed a sales contract with Ningxia Zhonghuan. Jingsheng will deliver automated crystal growing furnace to Ningxia Zhonghuan. The contract value reaches RMB6.08bn (VAT-included). Product delivery will begin in Nov 2021 while the actual delivery schedule will be subject to Ningxia Zhonghuan's notice. Cash collection will be divided into five stages: (1) down-payment, (2) product delivery, (3) product acceptance, (4) testing, and (5) warranty.
- Jingsheng continues to be the major beneficiary of Zhonghuan's aggressive capex growth. Zhonghuan has been Jingsheng's largest customer. According to Zhonghuan's latest share placement plan, Zhonghuan plans to raise a total of RMB9bn to finance the capex on 50GW of G12 monowafer capacity. Ningxia Zhonghuan will be the entity to execute the project. The construction lead time is expected to be 15 months. Therefore, we forecast the revenue contribution to Jingsheng will be in 2022E-23E.
- TP revised up. We lift our TP to RMB112 from RMB77.5, as we roll over our valuation base to 2022E as the solid backlog offers good visibility to the earnings in 2022E-23E. Our new TP is based on 56x FY22E earnings on the back of 56% EPS CAGR in 2021E-23E (equivalent to 1x PEG).
- Risk: 1) Weaker or slower-than-expected solar power capacity expansion; 2) lower-than-expected gross margin; (3) unsuccessful acquisition.

Earnings Summary

(YE 31 Dec)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue (RMB mn)	3,110	3,811	7,008	11,868	14,761
YoY growth (%)	23	23	84	69	24
Net income (RMB mn)	637	858	1,484	2,598	3,238
EPS (RMB)	0.50	0.67	1.15	2.02	2.52
YoY growth (%)	(5)	35	73	75	25
Consensus EPS (RMB)	N/A	N/A	1.16	2.02	2.52
P/E (x)	156.5	116.3	67.3	38.4	30.8
P/B (x)	21.9	19.1	15.2	11.3	8.6
Yield (%)	0.1	0.2	0.3	0.5	0.6
ROE (%)	14.8	17.5	25.2	33.7	31.7
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIS estimates

BUY (Maintain)

Target Price RMB112.00 (Previous TP RMB 77.50)
Up/Downside +44%
Current Price RMB 77.67

China Capital Goods

Wayne Fung, CFA (852) 3900 0826 waynefung@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	99,850
Avg 3 mths t/o (RMB mn)	968
52w High/Low (RMB)	79.74/24.70
Total Issued Shares (mn)	1,286
Source: Bloomberg	

Shareholding Structure

Shaoxing Shangyu Jingsheng	
Invt. Mgmt. and Consulting	48.28%
QIU Minxiu	2.97%
CAO Jianwei	2.77%

Source: Company data

Share Performance

	Absolute	Relative
1-mth	8.3%	12.5%
3-mth	54.0%	67.3%
6-mth	72.3%	92.4%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: Pan-China CPA

Related Reports

- Zhejiang Jingsheng (300316 CH, BUY) – Acquisition to help tap into solar cell equipment – 2 Aug 2021
- Zhejiang Jingsheng (300316 CH, BUY) Robust solar capex;
 Earnings & TP revised up 2 Jul
- 3. Zhejiang Jingsheng (300316 CH, BUY) – Riding on the wave of large wafers – 18 Feb 2021



Figure 1: Change in earnings forecast

	Ne w				Old		Diff			
(RMBmn)	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	
Revenue	7,008	11,868	14,761	7,008	10,280	12,776	0%	15 %	16 %	
Crystal growing eqpt.	5,115	9,207	11,508	5,115	7,672	9,590	0%	20%	20%	
Intelligent processing eqpt.	1,075	1,667	2,084	1,075	1,613	2,017	0%	3%	3%	
Sapphire products	272	339	407	272	339	407	0%	0%	0%	
Eqpt. modification	137	164	197	137	164	197	0%	0%	0%	
Others	409	491	565	409	491	565	0%	0%	0%	
COGS	(4,487)	(7,498)	(9,311)	(4,487)	(6,531)	(8,101)	0%	15%	15%	
Gross profit (mn)	2,520	4,370	5,450	2,520	3,749	4,674	0%	17%	17%	
SG&A expenses	(280)	(451)	(531)	(280)	(391)	(460)	0%	15%	16%	
R&D expenses	(420)	(712)	(886)	(420)	(617)	(767)	0%	15%	16%	
Core operating profit	1,766	3,112	3,919	1,764	2,660	3,349	0%	17%	17%	
Impairment losses	(162)	(220)	(287)	(159)	(197)	(252)	2%	12 %	14%	
Pre-tax profit	1,725	3,022	3,767	1,727	2,593	3,233	0%	17%	17%	
Income tax	(243)	(426)	(531)	(244)	(366)	(456)	0%	17%	17%	
Minority interest	3	2	2	3	2	2	0%	0%	0%	
Net profit	1,484	2,598	3,238	1,486	2,230	2,779	0%	17%	17%	
EPS (RMB)	1.15	2.02	2.52	1.16	1.73	2.16	0%	17%	17%	
BVPS (RMB)	5.09	6.88	9.00	5.10	6.60	8.41	0%	4%	7%	
ROE	25.2%	33.7%	31.7%	25.2%	29.7%	28.8%	0.0ppt	4.1ppt	2.9ppt	

Source: Company data, CMBIS estimates


Figure 2: CPIA estimates large wafer (M10/G12) will account for 50% share in 2021, from 2.5% in 2020

Figure 3: Jingsheng's total backlog reached RMB11.5bn (including RMB644mn from semiconductor) as at end-Jun 2021 (RMB bn) 14.0 12.0 0.64 0.56 10.0

0.39

■PV backlog

0.44



Semiconductor backlog

8.0 6.0

4.0

2.0

0.0

Source: Company data, CMBIS Source: CPIA, CMBIS



Figure 4: Announced capacity expansion plans by major wafer makers in 1H21

Date of announcement	Company	Туре	Capacity Location (GW)	Commencement	Investment amount (RMB bn)	Capex/GW RMB mn
Jan-21	Gaojing Solar	Ingot pulling/wafer slicing	50 Wafer: Zhuhai, Guangdong; Ingot: Ningxia	Phase 1: 15GW (2021)	17.0	340
				Phase 2 & 3: 35GW (2023)		
Feb-21	Zhonghuan	Ingot pulling/wafer slicing	50 Yinchuan, Ningxia	n/a	12.0	240
	JYT	Ingot pulling/wafer slicing	24 Leshan, Sichuan	Phase 1: 12GW	7.0	292
	Shangji	Ingot pulling/wafer slicing	10 Baotao, Inner Mongolia	2022	3.5	350
Mar-21	JA Solar	Ingot pulling/wafer slicing	20 Baotao, Inner Mongolia	2023	5.0	251
	Shuangliang	Ingot pulling/wafer slicing	20 Baotao, Inner Mongolia	n/a	7.0	350
Apr-21	Canadian Solar	Ingot pulling/wafer slicing	10 Xining, Qinghai	2022	3.0	300
	Total		184	_	54.5	296


Source: Company data, news reports, CMBIS estimates

Figure 5: Capacity expansion by major wafer manufacturers

	2019	2020	2021E	2022E	2020	2021E	2022E
Wafer capacity (GW)	Additions						
LONGi	42	85	110	130	43	25	20
Zhonghuan	33	55 [*]	85	135	22	30	50
Jinko	15	26	33	35	11	8	2
JA Solar	8	18 ¹	32	40	10	14	8
JYT	2	7	17	32	5	10	15
Shangji Automation	2	13	30	35	11	17	5
Huantai (Meike)	3	3	15	15	0	12	0
Tongwei & Trina	0	0	8	15	0	8	8
Gaojing Solar	0	0	15	30	0	15	15
Solargiga	4	3	9	20	-0	5	12
Others	15	20	20	20	5	0	0
Total	124	230	373	507	106	143	134


Source: Company data, news reports, CMBIS estimates

Figure 6: Jingsheng's forward P/E band



Source: Bloomberg, Company data, CMBIS estimates

Figure 7: Jingsheng's forward P/B band



Source: Bloomberg, Company data, CMBIS estimates



Financial Summary

Income statement	Cash flow
------------------	-----------

YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E
Revenue	3,110	3,811	7,008	11,868	14,761	PAT	624	852	1,481	2,596	3,236
Crystal growing eqpt.	2,173	2,623	5,115	9,207	11,508	D&A	114	136	137	153	172
Intelligent processing eqpt.	504	552	1,075	1,667	2,084	Change in working capital	(47)	(124)	(370)	(1,375)	(1,902)
Eqpt. modification	165	101	137	164	197	Others	88	90	(29)	(39)	(43)
Sapphire products	66	194	272	339	407	Operating cash flow	779	954	1,218	1,336	1,463
Others	201	341	409	491	565						
cogs	(2,004)	(2,416)	(4,487)	(7,498)	(9,311)	CAPEX	(95)	(229)	(265)	(260)	(260)
Gross profit	1,105	1,395	2,520	4,370	5,450	Others	(441)	(54)	(88)	(84)	(82)
						Investing cash flow	(536)	(283)	(353)	(344)	(342)
S&M expenses	(46)	(33)	(56)	(95)	(118)						
G&A expenses	(126)	(136)	(224)	(356)	(413)	Proceeds from fund raising	1	18	-	-	-
R&D expenses	(186)	(227)	(420)	(712)	(886)	Changes in borrowings	(45)	(44)	(10)	10	10
Other opex	(15)	(39)	(54)	(94)	(114)	Dividends paid	(135)	(132)	(174)	(297)	(520)
Core operating profit	733	959	1,766	3,112	3,919	Others	5	(209)	(2)	(2)	(2)
Impairment losses	(97)	(137)	(162)	(220)	(287)	Financing cash flow	(174)	(366)	(185)	(289)	(512)
Other expenses and incomes	70	129	67	36	21						
						Net change in cash	69	305	680	703	609
Pre-tax profit	721	992	1,725	3,022	3,767	Cash at the beginning	473	542	847	1,528	2,231
Income tax	(97)	(140)	(243)	(426)	(531)	Forex change, net	(0)	0	-	-	-
Minority interest	13	6	3	2	2	Less: restricted cash	37	88	-	-	-
Net profit	637	858	1,484	2,598	3,238	Cash at the end	542	847	1,528	2,231	2,840

Balance sheet Key ratios

YE 31 Dec (RMB mn)	FY19A	FY20A	FY21E	FY22E	FY23E	YE 31 Dec	FY19A	FY20A	FY21E	FY22E	FY23E
Current assets	5,675	7,962	12,956	19,364	24,845	Revenue mix (%)					
Cash and restricted cash	582	938	1,619	2,322	2,931	Crystal growing eqpt.	70	69	73	78	78
Trade receivables	2,865	3,713	6,657	10,088	12,990	Intelligent processing eqpt.	16	14	15	14	14
Inventories	1,389	2,580	3,949	6,224	8,194	Eqpt. modification	5	3	2	1	1
Other current assets	839	731	731	731	731	Sapphire products	2	5	4	3	3
						Others	6	9	6	4	4
Non-current assets	2,187	2,536	2,783	3,014	3,229						
Long-term equity investment	503	824	943	1,067	1,194	YoY growth (%)					
Fixed assets	1,147	1,135	1,244	1,348	1,431	Revenue	23	23	84	69	24
Other non-current assets	537	577	596	598	604	Gross profit	10	26	81	73	25
Total assets	7,863	10,498	15,738	22,378	28,074	Net profit	9	35	73	75	25
Current liabilities	3,085	5,201	9,137	13,474	16,451	Operating efficiency					
ST borrowings	42	22	15	22	29	Gross margin	35.5	36.6	36.0	36.8	36.9
Trade payables	1,869	2,775	5,160	8,623	10,708	Core operating margin	23.6	25.2	25.2	26.2	26.6
Contract liabilities	1,007	2,003	3,560	4,428	5,314	Net profit margin	20.5	22.5	21.2	21.9	21.9
Other current liabilities	167	401	401	401	401						
						B/S ratios (%)					
Non-current liabilities	61	46	43	46	49	Net gearing	Net cash				
LT borrowings	36	11	8	11	14	Receivable turnover days	261	303	263	257	285
Other non-current liabilities	25	35	35	35	35	Inventory turnover days	167	190	170	156	178
Total liabilities	3,146	5,247	9,179	13,520	16,500	Payable turnover days	282	351	323	335	379
Share capital	1,284	1,286	1,286	1,286	1,286	Profitability (%)					
Reserves	1,448	1,528	1,528	1,528	1,528	ROE	14.8	17.5	25.2	33.7	31.7
Retained earnings	1,819	2,426	3,737	6,038	8,755	ROA	9.0	9.3	11.3	13.6	12.8
Shareholders' fund	4,551	5,240	6,551	8,851	11,569						
Minority interest	165	12	9	7	5	Per share data (RMB)					
Total equity	4,716	5,251	6,559	8,858	11,574	EPS	0.50	0.67	1.15	2.02	2.52
						DPS	0.10	0.14	0.23	0.40	0.50
						BVPS	3.54	4.08	5.09	6.88	9.00

Source: Company data, CMBIS estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIS Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.